GlassScriptPhysician profile
Mary K George
NPI 1689648727
$4,645.41
in general payments reported to CMS, 2019-2025
23 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $613 · 2021: $760 · 2022: $879 · 2023: $515 · 2024: $659 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.84 |
| Education | $131.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $887.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $669.81 | 2019-2022 | |
| Lilly USA, LLC | $661.53 | 2021-2025 | Zepbound, Mounjaro |
| Amgen INC. | $463.89 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $361.76 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Endo Pharmaceuticals INC. | $313.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.62 | 2019-2022 | |
| Exact Sciences Corporation | $155.63 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $142.55 | 2025 | Veozah |
| Biocompatibles, INC. | $138.84 | 2019 | |
| Medicure Pharma INC. | $109.33 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $104.85 | 2019-2021 | |
| Abbvie INC. | $99.18 | 2019-2021 | |
| Pfizer INC. | $67.56 | 2020-2024 | |
| Watermark Medical, INC. | $56.40 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $46.25 | 2019-2025 | Tremfya |
| Medtronic USA, INC. | $43.22 | 2019 | |
| Medtronic, INC. | $43.18 | 2024 | Magnifuse Bone Graft |
| Echosens North America, INC. | $36.89 | 2025 | Fibroscan |
| Nevro Corp. | $25.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.85 | 2023 | Quviviq |
| Abbott Laboratories | $17.35 | 2022 | |
| Vertos Medical, INC. | $14.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.